Paul Workman is a researcher at the Institute of Cancer Research.[1]He is a member of the Royal Society and the Institute of Cancer Research.[2]He was inducted into the Fellow of the Academy of Medical Sciences.[3]Workman is a Fellow of the Royal Society and a Fellow of the Royal Society of Chemistry.[3]
He is Harrap Professor of Pharmacology and Therapeutics at the ICR, as well as the former Head of the Division of Cancer Therapeutics and former Director of the Cancer Research UK Cancer Therapeutics Unit from 1997-2016 - a period of 18 years.[4]He is chief executive of the Institute of Cancer Research in London, which conducted the research.[5]He is a Fellow of the Royal Society and has been awarded the prestigious American Association of Cancer Research Team Science Award, amongst numerous other accolades.[6]
Events - Primer's event detection algorithm clusters and summarizes multiple documents describing real-world events.
Mentions - Mentions are snippets of text that map to a person.
Docs - The number of documents that match to a person in Primer's corpus of news articles.
Full tech explainer here.
Remember to check the sources and follow Wikipedia's guidelines.
Institute of Cancer Research
21
1122
776
Patients with advanced cancer saw tumours vanish during trials of an “exciting” new drug. The study was designed to test the safety of berzosertib when taken for cancers including breast and bowel. It is unusual to see a clinical response to drugs at this stage. Berzosertib belongs to a new class of precision drugs that block a DNA repair protein called ATR. Colleague Professor Paul Workman said, “It’s exciting that the first clinical trial of a drug targetting a key player in the DNA repair process had such promising results.”[47]
06/24/2020
Genetic screening for prostate cancer in GP surgeries could detect undiagnosed cases in otherwise healthy men at an early stage, new research suggests. More than a third of them - seven out of the 18 - were diagnosed with prostate cancer. "This is an exciting early pilot study, which for the first time in the UK demonstrates that genetic screening for prostate cancer is safe, feasible and potentially effective," said Professor Paul Workman, chief executive of the ICR. The study was funded by Cancer Research UK, the National Institute for Health Research and the European Research Council.[45]
05/31/2020
The drug is a result of UK-based Exscientia. “We believe that this entry of DSP-1181, created using AI, into clinical studies is a key milestone in drug discovery, ” said Andrew Hopkins, CEO of Exscientia. AI is used for analysing patient data and diagnosis but this is the first time it has been deployed for drug development. Paul Workman, chief executive of The Institute of Cancer Research in the UK was involved in the research. He said he was excited to see the first example of a new drug entering human clinical trials created by scientists using AI.[44]
02/26/2020